Apricus Biosciences Names Brian Dorsey Chief Development Officer

(RTTNews) - Apricus Biosciences, Inc. (APRI) Tuesday announced the appointment of Brian Dorsey as the company's Chief Development Officer, a newly established position, effective immediately.

Dorsey brings to Apricus over 20 years of experience in the pharmaceutical industry across early- and late-stage development programs, as well as with marketed products. He will report to Richard Pascoe, Apricus' Chief Executive Officer.

In a related matter, the company also announced the departure of Edward Cox, Vice President, Commercial Development, and Dr. Susan Meier-Davis, Vice President, Safety.

Dorsey has served in the Pharmaceutical and Biotechnology industries for over 20 years where he has provided high-level drug development, regulatory and QC/QA leadership of pharmaceutical candidates from early development to FDA approval.

He has held various senior management roles with pharmaceutical companies, most recently at Pernix Therapeutics as Senior Vice President Pharmaceutical Development.

Prior to this, Dorsey held managerial positions of increasing responsibility at Somaxon Pharmaceuticals, Baxter Bioscience and Pfizer Global Research and Development.